Citius Oncology (CTOR) Competitors $0.66 +0.02 (+2.34%) Closing price 04:00 PM EasternExtended Trading$0.64 -0.02 (-3.05%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CTOR vs. OCGN, CYBN, IKT, TLSA, LRMR, MOLN, PBYI, GLSI, NBTX, and NLTXShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Ocugen (OCGN), Cybin (CYBN), Inhibikase Therapeutics (IKT), Tiziana Life Sciences (TLSA), Larimar Therapeutics (LRMR), Molecular Partners (MOLN), Puma Biotechnology (PBYI), Greenwich LifeSciences (GLSI), Nanobiotix (NBTX), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Ocugen Cybin Inhibikase Therapeutics Tiziana Life Sciences Larimar Therapeutics Molecular Partners Puma Biotechnology Greenwich LifeSciences Nanobiotix Neoleukin Therapeutics Ocugen (NASDAQ:OCGN) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends. Which has higher valuation & earnings, OCGN or CTOR? Citius Oncology has lower revenue, but higher earnings than Ocugen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcugen$4.06M51.27-$63.08M-$0.19-3.75Citius OncologyN/AN/A-$21.15MN/AN/A Do analysts rate OCGN or CTOR? Ocugen currently has a consensus target price of $6.33, indicating a potential upside of 789.51%. Citius Oncology has a consensus target price of $3.00, indicating a potential upside of 379.23%. Given Ocugen's higher possible upside, equities research analysts plainly believe Ocugen is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Citius Oncology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is OCGN or CTOR more profitable? Citius Oncology has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. Citius Oncology's return on equity of -43.67% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Ocugen-532.51% -154.75% -90.79% Citius Oncology N/A -43.67%-9.74% Does the MarketBeat Community believe in OCGN or CTOR? Ocugen received 112 more outperform votes than Citius Oncology when rated by MarketBeat users. However, 100.00% of users gave Citius Oncology an outperform vote while only 71.07% of users gave Ocugen an outperform vote. CompanyUnderperformOutperformOcugenOutperform Votes11371.07% Underperform Votes4628.93% Citius OncologyOutperform Votes1100.00% Underperform VotesNo Votes Does the media favor OCGN or CTOR? In the previous week, Ocugen had 1 more articles in the media than Citius Oncology. MarketBeat recorded 2 mentions for Ocugen and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.87 beat Ocugen's score of 0.94 indicating that Citius Oncology is being referred to more favorably in the news media. Company Overall Sentiment Ocugen Positive Citius Oncology Very Positive Which has more volatility & risk, OCGN or CTOR? Ocugen has a beta of 3.88, suggesting that its share price is 288% more volatile than the S&P 500. Comparatively, Citius Oncology has a beta of -0.63, suggesting that its share price is 163% less volatile than the S&P 500. Do insiders and institutionals believe in OCGN or CTOR? 10.3% of Ocugen shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 4.3% of Ocugen shares are owned by company insiders. Comparatively, 4.6% of Citius Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryCitius Oncology beats Ocugen on 8 of the 14 factors compared between the two stocks. Remove Ads Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.79M$6.91B$5.63B$8.12BDividend YieldN/A2.73%4.56%4.01%P/E RatioN/A7.2524.5119.05Price / SalesN/A224.46381.7992.83Price / CashN/A65.6738.1634.64Price / Book-2.856.496.934.35Net Income-$21.15M$142.41M$3.20B$247.23M7 Day Performance2.62%-2.75%-2.17%-0.43%1 Month Performance-47.39%-4.44%3.14%-3.68%1 Year PerformanceN/A-8.37%11.11%2.00% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius OncologyN/A$0.66+2.3%$3.00+358.0%N/A$46.87MN/A0.00N/ANews CoveragePositive NewsOCGNOcugen1.285 of 5 stars$0.57+6.1%$6.33+1,011.1%-57.3%$166.45M$4.06M-3.1780Analyst RevisionCYBNCybin2.9328 of 5 stars$7.65+1.1%$86.00+1,024.2%N/A$164.30MN/A-1.7550IKTInhibikase Therapeutics0.9852 of 5 stars$2.36+4.9%$6.50+175.4%+4.4%$163.69M$260,000.00-0.886News CoverageTLSATiziana Life Sciences0.6458 of 5 stars$1.55-1.3%N/A+177.5%$163.36MN/A0.008Short Interest ↑Positive NewsGap UpLRMRLarimar Therapeutics1.9892 of 5 stars$2.55-1.5%$20.13+689.2%-68.8%$162.71MN/A-2.2230Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpMOLNMolecular Partners2.3422 of 5 stars$4.03-7.0%$12.00+198.1%+10.8%$162.46M$4.97M-1.87180Gap DownPBYIPuma Biotechnology4.3751 of 5 stars$3.24-2.4%$7.00+116.0%-44.1%$160.74M$230.47M6.75200Positive NewsGLSIGreenwich LifeSciences2.2424 of 5 stars$12.21+1.8%$38.00+211.2%-47.7%$160.50MN/A-15.263News CoverageGap UpNBTXNanobiotix2.4476 of 5 stars$3.33+2.8%$12.00+260.4%-44.2%$156.95M$36.22M0.00100Short Interest ↓News CoverageGap UpNLTXNeoleukin TherapeuticsN/A$16.70-0.6%N/A-71.8%$156.95MN/A-5.3790High Trading Volume Remove Ads Related Companies and Tools Related Companies Ocugen Competitors Cybin Competitors Inhibikase Therapeutics Competitors Tiziana Life Sciences Competitors Larimar Therapeutics Competitors Molecular Partners Competitors Puma Biotechnology Competitors Greenwich LifeSciences Competitors Nanobiotix Competitors Neoleukin Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTOR Stock Free CTOR Stock Alerts